Yvon Lebranchu, MD, from the University François Rabelais in Tours, France, reported 30-month results in patients who were initially treated with mycophenolate mofetil (MMF) plus cyclosporine (CsA) and then randomized three months later to continue this regimen, or CsA therapy was stopped and replaced by SRL. The trial included 192 first-time renal allograft recipients at 16 centers throughout France.
Graft loss and patient survival were similar in the two treatment groups.
One patient in the SRL/MMF group had developed a malignancy versus six patients in the CsA group.